Diagnostic Center | March 23, 2024
AstraZeneca’s FLAURA2 Phase III trial showed favourable trend in EGFR-mutated advanced lung cancer
Combination shows consistent benefit across prespecified post-progression outcomes
Combination shows consistent benefit across prespecified post-progression outcomes
It is the first autotaxin inhibitor to be investigated in cancer patients
The validations confirm the completion of the applications and commence the scientific review process
The preventive and promotive approach of our traditional health care systems has played a significant role in modern age today
Launches collaborative centre for translational research in head and neck cancer
The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
Subscribe To Our Newsletter & Stay Updated
